Article (Scientific journals)
Efficacy and safety of currently marketed anti-osteoporosis medications
Reginster, Jean-Yves; NEUPREZ, Audrey; Dardenne, Nadia et al.
2014In Best Practice and Research. Clinical Endocrinology and Metabolism, 28, p. 809-34
Peer Reviewed verified by ORBi
 

Files


Full Text
Efficacy and safety of currently marketed anti-osteoporosis medications.pdf
Publisher postprint (341.77 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Osteoporosis; Treatment; Efficacy; Safety
Abstract :
[en] During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications.
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
NEUPREZ, Audrey ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Dardenne, Nadia  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Beaudart, Charlotte ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Efficacy and safety of currently marketed anti-osteoporosis medications
Publication date :
2014
Journal title :
Best Practice and Research. Clinical Endocrinology and Metabolism
eISSN :
1878-1594
Publisher :
Elsevier Science, Amsterdam, Netherlands
Volume :
28
Pages :
809-34
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 22 September 2014

Statistics


Number of views
90 (17 by ULiège)
Number of downloads
8 (7 by ULiège)

Scopus citations®
 
42
Scopus citations®
without self-citations
42
OpenCitations
 
36

Bibliography


Similar publications



Contact ORBi